Articles related to Pulmonology

The study’s findings offer a novel perspective on norepinephrine reuptake inhibitors’ impact on “upper airway stability during sleep and are significant to guide future pharmacotherapy development for OSA,” according to the authors. Additionally, the findings offer individuals who are unable to tolerate modern therapies, such as continuous positive airway pressure (CPAP) equipment, wider alternatives when seeking therapy for OSA.

The oral suspension formulation was developed for patients who have difficulty swallowing the tablet form of the PDE5 inhibitor.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.

An 18-year-old man comes to you for a sports physical. He is asymptomatic, with no limitation in his exercise capacity. He has a history of exercise-induced bronchospasm for which he takes a budesonide-formoterol inhaler. He does not smoke, drink alcohol, or use any drugs. There is no family history of cardiac disease or sudden death. What’s the next appropriate test?

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.